Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop

Journal of Immunology

Volumn 193, Issue 3, 2014, Pages 1485-1495

  Rösner, Thies ^a   Lohse, Stefan ^a   Peipp, Matthias ^a   Valerius, Thomas ^a   Derer, Stefanie ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CETUXIMAB; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MEMBRANE COFACTOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; ANTIGENS, CD55; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHO CELLS; COLONIC NEOPLASMS; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT PATHWAY, ALTERNATIVE; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE TARGETING; HUMANS; IMMUNOGLOBULIN G; NUCLEIC ACID AMPLIFICATION TECHNIQUES; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84906077227     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400329     Document Type: Article

References (41)

1. Dunkelberger, J. R., and W. C. Song. 2010. Complement and its role in innate and adaptive immune responses. Cell Res. 20: 34-50.
2. Adams, G. P., and L. M. Weiner. 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157.
3. Gelderman, K. A., S. Tomlinson, G. D. Ross, and A. Gorter. 2004. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25: 158-164.
4. Terui, Y., T. Sakurai, Y. Mishima, Y.Mishima, N. Sugimura, C. Sasaoka, K. Kojima, M. Yokoyama, N. Mizunuma, S. Takahashi, et al. 2006. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci. 97: 72-79.
5. Mamidi, S., M. Cinci, M. Hasmann, V. Fehring, and M. Kirschfink. 2013. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol. Oncol. 7: 580-594.
6. Bindon, C. I., G. Hale, and H. Waldmann. 1990. Complement activation by immunoglobulin does not depend solely on C1q binding. Eur. J. Immunol. 20: 277-281.
7. Cragg, M. S., S. M.Morgan, H. T. Chan, B. P. Morgan, A. V. Filatov, P. W. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101: 1045-1052.
8. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
9. Derer, S., P. Bauer, S. Lohse, A. H. Scheel, S. Berger, C. Kellner, M. Peipp, and T. Valerius. 2012. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. J. Immunol. 189: 5230-5239.
10. Dechant, M., W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W. Parren, J. G. van de Winkel, and T. Valerius. 2008. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 68: 4998-5003.
11. Klausz, K., S. Berger, J. J. Lammerts van Bueren, S. Derer, S. Lohse, M. Dechant, J. G. van de Winkel, M. Peipp, P. W. Parren, and T. Valerius. 2011. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci. 102: 1761-1768.
12. Brüggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166: 1351-1361.
13. Dangl, J. L., T. G. Wensel, S. L. Morrison, L. Stryer, L. A. Herzenberg, and V. T. Oi. 1988. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 7: 1989-1994.
14. Michaelsen, T. E., P. Garred, and A. Aase. 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 21: 11-16.
15. Michaelsen, T. E., I. Sandlie, D. B. Bratlie, R. H. Sandin, and O. Ihle. 2009. Structural difference in the complement activation site of human IgG1 and IgG3. Scand. J. Immunol. 70: 553-564.
16. Brekke, O. H., T. E. Michaelsen, and I. Sandlie. 1995. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol. Today 16: 85-90.
17. Roux, K. H., L. Strelets, and T. E. Michaelsen. 1997. Flexibility of human IgG subclasses. J. Immunol. 159: 3372-3382.
18. Rösner, T., S. Derer, C. Kellner, M. Dechant, S. Lohse, G. Vidarsson, M. Peipp, and T. Valerius. 2013. An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. Br. J. Haematol. 161: 282-286.
19. Beyer, T., S. Lohse, S. Berger, M. Peipp, T. Valerius, and M. Dechant. 2009. Serum-free production and purification of chimeric IgA antibodies. J. Immunol. Methods 346: 26-37.
20. Stapleton, N. M., J. T. Andersen, A. M. Stemerding, S. P. Bjarnarson, R. C. Verheul, J. Gerritsen, Y. Zhao, M. Kleijer, I. Sandlie, M. de Haas, et al. 2011. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun. 2: 599.
21. Schlaeth, M., S. Berger, S. Derer, K. Klausz, S. Lohse, M. Dechant, G. A. Lazar, T. Schneider-Merck, M. Peipp, and T. Valerius. 2010. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci. 101: 1080-1088.
22. Oganesyan, L. P., G. M. Mkrtchyan, S. H. Sukiasyan, and A. S. Boyajyan. 2009. Classic and alternative complement cascades in post-traumatic stress disorder. Bull. Exp. Biol. Med. 148: 859-861.
23. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway revisited. J. Cell. Mol. Med. 12: 1074-1084.
24. Wiesmann, C., K. J. Katschke, J. Yin, K. Y. Helmy, M. Steffek, W. J. Fairbrother, S. A. McCallum, L. Embuscado, L. DeForge, P. E. Hass, and M. van Lookeren Campagne. 2006. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444: 217-220.
25. Koefoed, K., L. Steinaa, J. N. Søderberg, I. Kjær, H. J. Jacobsen, P. J. Meijer, J. S. Haurum, A. Jensen, M. Kragh, P. S. Andersen, and M. W. Pedersen. 2011. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 3: 584-595.
26. Duncan, A. R., and G. Winter. 1988. The binding site for C1q on IgG. Nature 332: 738-740.
27. Painter, R. H. 1984. The C1q receptor site on human immunoglobulin G. Can. J. Biochem. Cell Biol. 62: 418-425.
28. Bindon, C. I., G. Hale, M. Brüggemann, and H. Waldmann. 1988. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 168: 127-142.
29. Natsume, A., M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, and R. Niwa. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68: 3863-3872.
30. Michaelsen, T. E., A. Aase, C. Westby, and I. Sandlie. 1990. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand. J. Immunol. 32: 517-528.
31. Mollnes, T. E., K. Høgasen, B. F. Hoaas, T. E. Michaelsen, P. Garred, and M. Harboe. 1995. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand. J. Immunol. 41: 449-456.
32. Goers, J. W., and R. R. Porter. 1978. The assembly of early components of complement on antibody-antigen aggregates and on antibody-coated erythrocytes. Biochem. J. 175: 675-684.
33. Campbell, R. D., A. W. Dodds, and R. R. Porter. 1980. The binding of human complement component C4 to antibody-antigen aggregates. Biochem. J. 189: 67-80.
34. Lucisano Valim, Y. M., and P. J. Lachmann. 1991. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin. Exp. Immunol. 84: 1-8.
35. Giuntini, S., D. C. Reason, and D. M. Granoff. 2012. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect. Immun. 80: 187-194.
36. Olafsen, T., C. K. Munthe Lund, O. S. Bruland, I. Sandlie, and T. E. Michaelsen. 1999. Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. Cancer Immunol. Immunother. 48: 411-418.
37. Spendlove, I., J. M. Ramage, R. Bradley, C. Harris, and L. G. Durrant. 2006. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol. Immunother. 55: 987-995.
38. Ikeda, J., E. Morii, Y. Liu, Y. Qiu, N. Nakamichi, R. Jokoji, Y. Miyoshi, S. Noguchi, and K. Aozasa. 2008. Prognostic significance of CD55 expression in breast cancer. Clin. Cancer Res. 14: 4780-4786.
39. Wu, J., L. Lei, S. Wang, D. Gu, and J. Zhang. 2012. Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J. Biomed. Biotechnol. 2012: 587672.
40. Durrant, L. G., M. A. Chapman, D. J. Buckley, I. Spendlove, R. A. Robins, and N. C. Armitage. 2003. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 52: 638-642.
41. Ravindranath, N. M., and C. Shuler. 2007. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 103: 231-239.